Emergent BioSolutions (EBS) Faces Challenges as TEVA Wins Patent Dispute - Chardan
Tweet Send to a Friend
Chardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $86.00 price target on Emergent BioSolutions (NYSE: EBS) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
